VENT-03
Phase 2Small molecule
VENT-03 is one of 30 small molecule programs targeting Cutaneous Lupus Erythematosus. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
29
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
32 competitors in Cutaneous Lupus Erythematosus
#DrugCompanyPhaseTrials
1BMS-986165
Bristol-Myers SquibbApproved
Xeljanz
PPrism Pharmaceuticals
Approved
Trexall
Alnylam PharmaceuticalsPhase 3
Plaquenil
Alnylam PharmaceuticalsPhase 3
Saphnelo
AstraZenecaPhase 3
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Jyseleca
GileadPhase 2
Litifilimab
BiogenPhase 3
Prograf
VVeloxis Pharmaceuticals
Phase 2
Sotyktu
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for VENT-03. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- VVentus Therapeutics U.S., Inc.